Multicenter, double-blind, placebo-controlled trial of triamcinolone acetonide nasal aerosol in the treatment of perennial allergic rhinitis

Spector, S.; Bronsky, E.; Chervinsky, P.; Lotner, G.; Koepke, J.; Selner, J.; Pearlman, D.; Tinkelman, D.; Weakley, S.; Alderfer, V.

Annals of Allergy 64(3): 300-305

1990


ISSN/ISBN: 0003-4738
PMID: 2178497
Document Number: 359968
In a double-blind study involving 205 patients with perennial allergic rhinitis, statistically significantly greater symptomatic improvements were evident following the administration of 200 micrograms/day triamcinolone acetonide aerosol than following placebo. These improvements were evident as early as week 1 and were sustained throughout the 12-week study. They were accompanied by greater reductions in nasal eosinophils. Triamcinolone acetonide aerosol was well tolerated and had no effect on serum cortisol levels.

Document emailed within 1 workday
Secure & encrypted payments